Inhibitory receptors of the immune system: Functions and therapeutic implications

Cellular and Molecular Immunology

Volumn 6, Issue 6, 2009, Pages 407-414

  Zhang, Jian ^a   Xiao, Xiang ^a   Liu, Wentao ^a   Demirci, Gulcin ^a   Li, Xian C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Immunity; Inflammation; Negative pathways; Regulation; Tolerance

Indexed keywords

B7 ANTIGEN; CARRIER PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 MONOCLONAL ANTIBODY; FC RECEPTOR; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS I BINDING INHIBITORY RECEPTOR; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; ANTIGEN; BTLA IMMUNOGLOBULIN; CYTOKINE; IMMUNOGLOBULIN; PD 1 ANTIGEN; RECEPTOR;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; DNA POLYMORPHISM; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; CYTOKINE PRODUCTION; IMMUNITY; IMMUNOREGULATION; INHIBITION KINETICS; MODULATION; NEGATIVE FEEDBACK; RECEPTOR BINDING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; HOMEOSTASIS; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; RECEPTORS, IMMUNOLOGIC;

EID: 73649101301     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2009.52     Document Type: Review

References (67)

1. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med. 2002;195:9-14.
2. Sprent J, Surh CD. Generation and maintenance of memory T cells. Curr Opin Immunol. 2001;13:248-254.
3. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-562.
4. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev. 2009;229:271-293.
5. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 2007;8:1-7.
6. Lanier LL. NK cell receptors. Annu Rev Immunol. 1998; 16:359-393.
7. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005; 23:225-274.
8. yokoyama WM, Kim S. How do natural killer cells find self to achieve tolerance? Immunity. 2006;24:294-257.
9. Yokoyama WM, Kim SH, French AR. The dynamic life of natural killer cells. Annu Rev Immunol. 2004;22:405-429.
10. Kumar V, McNerney ME. A new self: MHC-class Iindependent natural killer cell self-tolerance. Nat Rev Immunol. 2005;5:363-374.
11. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: Dendritic cells and NK cells take centre stage. Nature Rev Immunol. 2005;5:112-124.
12. Johansson S, Johansson M, Rosmaraki E, et al. Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J Exp Med. 2005; 201:1145-1155.
13. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436:709-713.
14. Yu J, Heller G, Chewning J, Kim S, Yokoyama WM, Hsu KC. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol. 2007;179:5977-5989.
15. Hamerman JA, Ogasawara K, Lanier LL. NK cells and innate immunity. Curr Opin Immunol. 2005;17:1-7.
16. Ruggeri L, Mancusi A, Capanni M, Martelli M, Velardi A. Exploitation of allorective NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol. 2005;17:211-217.
17. Yu G, Xu X, Vu MD, Kilpatrick ED, Li XC. NK cells promote transplant tolerance by killing donor antigen-presenting cells. J Exp Med. 2006;203:1851-1858.
18. Garrod KR, Wei SH, Parker I, Cahalan MD. Natural killer cells actively patrol peripheral lymph nodes forming stable conjugates to eliminate MHC-mismatched targets. Proc Nat Acad Sci U S A. 2007;104:12081-12086.
19. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
20. Beilke JN, Kuhl NR, Kaer LV, Gill RG. NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nat Med. 2005;11:1059-1065.
21. + T cells rapidly acquire NK1.1 and NK cell-associated molecules upon stimulation in vitro and in vivo. J Immunol. 2000;165:3673-3679.
22. Hanna J, Bechtel P, Zhai Y, Youssef F, McLachlan K, Mandelboim O. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol. 2004;173:6547-6563.
23. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. 2001;1:220-228.
24. Khoury SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity. 2004;20:529-538.
25. Krummel MK, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459-465.
26. Perez VL, Parijs LV, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 1997;6:411-417.
27. + T cells, IFN-γ, and CTLA-4. J Clin Invest. 1998;101:2446-2455.
28. Waterhouse P, Penninger JM, Timms E, et al. Lympho-proliferative disorders with early lethality in mice deficient in ctla-4. Science. 1995;270:985-988.
29. Bluestone JA. Is CTLA-4 a master switch for peripheral T cell tolerance? J Immunol. 1997;158:1989-1993.
30. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116-126.
31. Munn DH, Sharma MD, Lee JR, et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioygenase. Science. 2002;297:1867-1870.
32. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002;3:1097-1101.
33. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science. 1990;248:1349-1356.
34. + regulatory T cell function. Science. 2008;322:271-275.
35. Ariyan C, Salvalaggio P, Fecteau S, et al. Cutting edge: transplantation tolerance through enhanced CTLA-4 expression. J Immunol. 2003;171:5673-5677.
36. Fecteau S BG, Freitas A, Ariyan C, Sayegh MH, Rothstein DM. CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nat Immunol. 2001;2:58-63.
37. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-258.
38. Okazaki T, Iwai Y, Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol. 2002; 14:779-782.
39. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291:319-322.
40. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141-151.
41. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates Graft-versus-host disease lethality by an IFN-γ-dependent mechanism. J Immunol. 2003;171:1272-1277.
42. Ansari MJI, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003;198:63-69.
43. Ozkaynak E, Wang L, Goodearl A, et al. Programmed death-1 targeting can promote allograft survival. J Immunol. 2002;169: 6546-6553.
44. Subudhi SK, Zhou P, Yerian LM, et al. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest. 2004;113:694-700.
45. Yang J, Popoola J, Khandwala S, et al. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation. 2008;117:660-669.
46. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111-122.
47. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467-477.
48. Murphy K, Nelson CA, Sedý JR. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol. 2006; 6:671-681.
49. Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003;4:670-679.
50. + T cells through interaction with herpesvirus entry mediator. Nat Immunol. 2008;9:176-185.
51. Tao R, Wang L, Murphy KM, Fraser CC, Hancock WW. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J Immunol. 2008;180:6649-6655.
52. Nimmeriahn F, Ravetch JV. Fc receptors as regulators of immunity. Advances in Immunology. 2007;96:179-204.
53. + anti-DNA plasma cells. Nat Immunol. 2005;6:99-106.
54. Boruchov AM, Heller G, Veri MC, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory Fc receptors on human dendritic cells mediate opposing functions. J Clin Invest. 2005; 115:2914-2923.
55. McGaha TL, Karlsson MCI, Ravetch JV. FcγRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice. J Immunol. 2008;180:5670-5679.
56. Tha-In T, Bayry J, Metsalaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol. 2008;29:608-615.
57. Zheng XX, Steele AW, Hancock WW, et al. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol. 1997;158:4507-4513.
58. Zheng XX, Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB. Administration of noncytolytic IL-10/Fc in murine models of LPS induced septic shock and allogeneic islet transplantation. J Immunol. 1995;154:5590-5600.
59. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. IL-10 deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
60. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998;16:137-161.
61. Lin HY, Lodish HF. Receptors for the TGF-β superfamily: multiple polypeptides and serine/threonine kinases. Trends Cell Biol. 1993;3:14-19.
62. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med. 2003;198:1875-1886.
63. Kehrl JH. Transforming growth factor-β: an important mediator of immunoregulation. Int J Cell Cloning. 1991;9:438-450.
64. + Regulatory T Cells by Peripheral Expansion. J Immunol. 2004;173:7259-7268.
65. Li MO, Wan YY, Sanjabi S, Robertson AL, Flavell RA. Transforming growth factor-β regulation of immune responses. Annu Rev Immunol. 2006;24:99-146.
66. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T cell function. Nature. 2007;450:566-569.
67. Bettni M, vignali DA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol. 2009;21: 612-618.